Related Experiment Video
Updated: Jan 17, 2026
10:10
Reverse Total Shoulder Arthroplasty
Published on: July 5, 2011
43.8K
Angiotensinogen II Receptor Blockers May Decrease Risk of Adhesive Capsulitis After Rotator Cuff Repair
Cody S Lee1, Jordan Cook Serotte1, Sai Reddy2
1Department of Orthopaedic Surgery, University of Chicago, Chicago, Illinois, U.S.A.
Arthroscopy, Sports Medicine, and Rehabilitation
|September 22, 2025
Summary
Angiotensin II receptor blockers (ARBs) may reduce the risk of adhesive capsulitis (AC) after rotator cuff surgery. ARBs did not impact the need for manipulation under anesthesia or lysis of adhesions once AC developed.
Area of Science:
- Orthopedic Surgery
- Pharmacology
- Epidemiology
Background:
- Adhesive capsulitis (AC) is a potential complication following arthroscopic rotator cuff repair.
- Antifibrotic medications are commonly prescribed, but their effect on AC development is not well-established.
Purpose of the Study:
- To investigate the association between commonly prescribed antifibrotic medications and the incidence of adhesive capsulitis (AC) after arthroscopic rotator cuff repair.
Main Methods:
- A retrospective cohort study utilizing the Mariner data set (2010-2022).
- Patients aged 40-65 undergoing rotator cuff repair were analyzed based on pre-operative and peri-operative medication use (ARBs, ACE inhibitors, COX-2 inhibitors, statins).
- Development of AC, manipulation under anesthesia (MUA), and arthroscopic lysis of adhesions (LOA) within 6 months post-surgery were identified via medical codes.
Main Results:
- Out of 183,563 patients, 4.62% developed postoperative AC.
- Patients prescribed angiotensin II receptor blockers (ARBs) demonstrated a statistically significant lower odds ratio (0.87, P=.04) for developing AC.
- No significant association was found between the studied medications and the odds of undergoing MUA or LOA.
Conclusions:
- Angiotensin II receptor blockers (ARBs) are associated with reduced odds of developing adhesive capsulitis (AC) post-arthroscopic rotator cuff repair.
- The use of ARBs did not influence the likelihood of requiring subsequent MUA or LOA once AC was diagnosed.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
01:25Aortic Regurgitation III: Medical Management
399
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
399